Related Experiment Video
Updated: Dec 18, 2025
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.1K
COMMD8 changes expression during initial phase of wasp venom immunotherapy
Karol Kempiński1, Jan Romantowski1, Agnieszka Maciejewska2
1Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
The Journal of Gene Medicine
|June 20, 2020
Summary
Hymenoptera venom immunotherapy (VIT) significantly alters Commd8 gene expression during the initial treatment phase. This finding suggests Commd8 may serve as a potential biomarker for monitoring VIT effectiveness in patients with Hymenoptera venom allergy.
Area of Science:
- Immunology
- Allergology
- Molecular Biology
Background:
- Hymenoptera venom allergy (HVA) poses a risk of life-threatening anaphylaxis.
- Venom immunotherapy (VIT) is the primary disease-modifying treatment for HVA, but its precise mechanisms are not fully understood.
- Gene expression analysis can elucidate tolerance induction during VIT.
Purpose of the Study:
- To investigate changes in the expression of 15 selected genes at the onset of VIT in HVA patients.
- To identify potential gene expression biomarkers associated with early VIT response.
Main Methods:
- Forty-five HVA patients undergoing wasp venom VIT were enrolled.
- Blood samples were collected before and after 3 months of VIT.
- Gene expression was analyzed using RT-PCR, with Commd8 identified as a key gene.
Main Results:
- Commd8 gene expression significantly decreased after initiating VIT, approaching levels seen in healthy controls (p = 0.012).
- Twelve of the 15 analyzed genes showed significantly different expression compared to healthy individuals.
- This suggests Commd8 is sensitive to early VIT interventions.
Conclusions:
- Commd8 gene expression is significantly altered during the initial phase of VIT.
- Commd8 shows potential as a biomarker for monitoring VIT efficacy in HVA patients.
- Further research is warranted to validate Commd8 as a reliable VIT biomarker.
